Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on X:
“Time to update my tissue agnostic precision oncology slide deck with new waterfall plots!
We’ve gone from 1 → 2 → now 3 FDA-approved NTRK inhibitors with repotrectinib joining larotrectinib and entrectinib. Fresh data just published in Nature Medicine.
This is what progress in tumor-agnostic therapy looks like. More to come ”
More posts featuring Vivek Subbiah
